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Summary. Therapeutic options for developing coun-
tries have to assure an optimum safety and efficacy
and low-cost antihaemophilic concentrates. A single
blind randomized crossover study was carried out in
12 previously treated HB patients, comparing the
pharmacokinetics (PK), thrombogenicity (TG) and
safety of two plasma-derived double-inactivated
(solvent/detergent heating at 100C, 30 min) factor
IX (FIX) concentrates, UMAN COMPLEX DI
(product A) [plasma-derived prothrombin concen-
trates (PCC)] and a high purity FIX concentrate
AIMAFIX DI (product B, HPFIX). In a non-bleeding
state, they received one single intravenous dose 50 IU
FIX kg)1 of PCC or HPFIX, and after a wash-out
period of 14 days, the other product. We evaluated
acute tolerance and determined PK parameters based
on FIX levels measured over a 50 h postinfusion
period. We studied fibrinogen, platelets, antithrom-
bin, F1 + 2, TAT, D-dimer, over a 360 min postin-
fusion period. Ten cases remained in on-demand
treatment for 6 months, five with PCC and five with
HPFIX. PK and anti-FIX inhibitors were repeated at
3 and 6 months. No inhibitors were detected. PK
values (PCC vs. HPFIX): clearence (CL;
mL h)1 kg)1) 5.2 ± 1.4 vs. 6.5 ± 1.4; the volume of
distribution at steady state (mL kg)1) 154.9 ± 54.9
vs. 197.5 ± 72.5; mean residence time (h) 29.7 ± 8.1
vs. 30.7 ± 9.2; T1/2 (h) 22.3 ± 7 vs. 23.5 ± 12.3;
incremental recovery (IR; U dL)1 U)1 kg)1)
0.96 ± 0.17 vs. 0.76 ± 0.13. HPFIX showed signifi-
cant lower IR and higher CL. There were no
differences in PK at 3 and 6 months. In TG,
significant increments in TAT and F1 + 2 at 30 min
and 6 h were found with PCC. Product B PK results
agrees with reported results for other HPFIX prep-
arations. Use of PCC product A has to consider its
thrombogenic activity.
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Introduction
There is a broad spectrum of treatment possibilities
for haemophilia B patients, including new highly
purified plasma-derived factor IX (FIX) concentrates
and products manufactured using recombinant DNA
technology [1,2]. Plasma-derived prothrombin con-
centrates (PCC) are highly effective, but occasional
thrombotic complications associated with their use
have been observed among haemophiliacs, this being
generally attributed to the accumulation of activated
vitamin K-dependent factors [3]; further purification
steps seem to have eliminated those complications
[4,5]. Therapeutic options for developing countries
are limited so we have to assure an optimum safety
and efficacy and low costs for the antihaemophilic
concentrates.
The aim of the present study was to compare the
pharmacokinetics (PK) and safety of two double-
inactivated FIX containing products, a high-purity
FIX concentrate (AIMAFIX DI) and a PCC (UMAN
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COMPLEX DI), titrated for its FIX content after
intravenous administration to haemophilia B
patients.
Patients, materials and methods
FIX concentrates
The UMAN COMPLEX DI (product A) contained
500 IU FIX, 500 IU factor II (FII) and 400 IU factor
X (FX) per vial. Antithrombin III (ATIII) and heparin
was added before lyophilization. Two different
batches were used in this study. Viral inactivation
was performed with solvent/detergent and heating of
the lyophilized product at 100C for 30 min.
The AIMAFIX DI (product B) contained 500 IU
FIX per vial and was prepared from PCC by affinity
chromatography on immobilized heparin. Three
different batches were used in the study. Viral
inactivation methods as described in product A.
Both products are prepared by Kedrion S.p.A (Cas-
telvecchio Pascoli, Italy).
Patients and study design
The study was carried out in one center (Banco
Municipal de Sangre, DC, Caracas, Venezuela)
according to a single blind randomized crossover
design. Written informed consent was obtained from
all patients. The study was reviewed and approved
by the Ethics Committee of the Banco Municipal de
Sangre, DC. Thirteen volunteers previously treated
haemophilia B patients (FIX < 2 U dL)1), aged 12–
36 years and with a mean weight of 61.4 ± 14.2 kg
were enrolled in this study. None of the patients had
a history of anti-FIX inhibitors. All were anti-human
immunodeficiency virus seronegative; antibodies for
hepatitis C virus were detected in six patients,
although none of them showed a serum ALT more
than 2.5 times the upper limit of normal. Patients
who did not use FIX concentrates or plasma during
the 7 days prior to infusion were randomized to
receive a single dose of either product A (seven
patients) or product B (six patients) while in a non-
bleeding state. After a wash-out period of 14 days all
patients were shifted to receive a single dose of the
other product. After the crossover study, 10 cases
remained on demand treatment for the following
6 months, using the last product received (five
received product A and five product B) as their sole
replacement therapy. Inhibitor detection by Bethesda
method [6] and pharmacokinetics studies were
evaluated in each case at 3 and 6 months of follow-
up.
Product administration
Prior to receiving the infusion, each case was
clinically evaluated. Dose was calculated according
to the weight and the FIX content reported on the
pertinent analytical certificate by the manufacturer.
Each patient received 50 U of FIX per kg of body
weight. The rate of infusion was of 2 mL min )1.
The time for infusion for the product A varied from
43 to 80 min (mean: 67.8 ± 14.4 SD) and for
product B varied from 15 to 42 min (mean:
30.9 ± 9.9 SD).
Acute tolerance evaluation
Vital signs, namely body temperature, pulse, respir-
atory rate and supine blood pressure were deter-
mined prior to during and after infusion, at the same
time clinical observation and adverse events were
also recorded.
Blood collection
Blood was collected by clean venipuncture from the
arm opposite to the one used for infusion of factor
concentrate, in 3.8% trisodium citrate (9:1 v/v) for
factor IX determinations and thrombogenicity (TG)
studies and in EDTA for platelet count.
Pharmacokinetics evaluation
Samples were collected prior to the start of infusion,
immediately after the end of infusion, and at 0.5, 1,
3, 6, 9, 12, 24, 30, 36 and 50 h postinfusion.
Aliquots of plasma were kept frozen at )70C until
analysed. FIX activity was analysed by one-step
method, using three plasma dilutions, in all plasma
samples obtained at the above-mentioned periods.
Each dilution was performed in duplicated by the
same technician. FIX Immunodepleted Substrate was
used (Helena Laboratories, Beaumont, TX, USA). A
local reference plasma obtained from 20 health
volunteers was calibrated against an International
Standard of FIX.
Pharmacokinetic parameters of the model were
estimated through a non-linear fitting procedure
using the computer program Excel. Non-compart-
ment method for the estimation of pharmacokinetic
parameters was used. The following pharmacokinet-
ic parameters were assessed: area under the curve
(AUC), computed using the trapezoidal rule; the area
under the first moment of the curve (AUMC) that is
the product of each point of the AUC for the
respective time; incremental recovery (IR): the peak
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level of FIX determined at the first hour after
infusion; mean residence time (MRT): the rate of
FIX decrease after infusion; clearence (CL): the
amount of plasma free of the drug/h; the volume of
distribution at steady state (Vdss); the maximal
concentration of FIX and the time when it is
achieved (Cmax and Tmax respectively); and the
terminal half-life (T1/2) of the FIX infused.
Thrombogenicity studies
Samples were taken prior to infusion and at 30, 180
and 360 min after. The following parameters were
evaluated by standard procedures: Fibrinogen
(Clauss method; Diagnostica Stago, Asniers, France),
platelets count, Thrombin–antithrombin complex
(Enzygnost TAT Micro; Behringwerke AG, Mar-
burg, Germany), prothrombin fragment F1 + 2
(Dade Behring, Marburg, Germany), antithrombin
III (Stachhrom; Diagnostica Stago), D-dimer (Asser-
achrom D-Di; Diagnostica Stago), as markers of the
activation of the haemostatic system. Results were
compared with the reference values obtained in our
laboratory from 20 healthy control.
Statistical analysis
Pharmacokinetics data were calculated according to
the ISTH recommendations [7–9]. All pharmacoki-
netic parameters were summarized with mean,
standard deviation and 95% confidence interval of
mean values for each combination of time with the
different type of preparation. Data analysis was
performed using stata 7.0 (Stata Corporation,
College Station, TX, USA) [10]. Paired two-tailed
Student’s t-test was used to compare mean values of
two products for each different pharmacokinetic
parameters and was used to evaluate the potential
TG of products A and B. In the crossover analysis
anova model (Fisher’s test) was used to compare
mean values of concentrations of AUC between the
product A and B and to evaluate their bioequiva-
lence. This model considered both period effect and
treatment effect and their interaction. In safety
analyses all reported P-values are two-sided. Signi-
ficance was assessed with a set at 0.05. Statistically
significant results are flagged by their degree
(*P < 0.05; **P < 0.01; ***P < 0.001) [11,12].
Results
Thirteen patients were enrolled and 12 patients
finished the study. Clinical and laboratory assess-
ments are summarized in Table 1. No adverse events
were observed with high purity FIX; one patient
during PCC infusion experienced a mild bronchial
asthma crisis treated with an aerosol inhaler.
Pharmacokinetics
In Table 2 we can observe the results of the analysed
pharmacokinetic parameters. The crossover study
showed significant differences between the pharma-
cokinetic behaviour of the two study products as the
mean of the values of the following PK parameters:
AUC, AUMC, IR and CL, resulted statistically
significant when comparing the pooled data for
patients treated with product A vs. B. Subjects
Table 1. Clinical and laboratory characteristics of patients.
Patient
Age
(years)
Factor
IX
(U dL)1)
Weight
(kg)
HAV
Ab HBsAg
HCV
Ab
HIV
1 + 2 Ab
Platelet
(109 L)1)
Hgb
(g dL)1) Hct
WBC
(109 L)1)
ALT
(U L)1)
AST
(U L)1)
1 32 0.4 79.7 Positive Negative Negative Negative 222 13.3 0.39 7.7 68 45
2 20 1 75 Negative Negative Positive Negative 236 13 0.39 6 57 61
3 15 1 48.5 Negative Negative Positive Negative 353 11.5 0.34 7.2 15 27
4 19 1 55.5 Negative Negative Positive Negative 186 13.1 0.40 5.8 32 27
5 15 1.4 58.8 Positive Negative Negative Negative 222 13.5 0.43 3.8 15 29
6 14 1.4 58 Positive Negative Positive Negative 267 12.7 0.40 4.4 30 18
7 14 1.2 61.7 Negative Negative Negative Negative 282 14.7 0.43 5.4 12 25
8 17 0.8 45.5 Negative Negative Negative Negative 221 12.9 0.40 5.1 30 26
9 12 0.9 36.5 Negative Negative Negative Negative 262 13.3 0.42 6.4 18 29
10 36 1 85 Positive Negative Positive Negative 338 11.9 0.36 6 33 37
11 27 1 73 Positive Negative Negative Negative 220 14.7 0.44 6.7 24 10
12 21 <1 69 Positive Negative Positive Negative 172 14.1 0.42 9.2 32 24
13 18 0.7 53 Negative Negative Negative Negative 207 15.6 0.47 7.7 30 24
Reference
values
62–138 130–400 13.5–17 40–54 4–11 <38 <40
HAV, Hepatitis A virus; HCV, Hepatitis C virus; Ab, Antibodies; Ag, Antigen.
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treated with product B (n ¼ 12) showed a lower
AUC, AUMC and IR while the same subjects treated
with product A showed a lower CL. Vdss resulted
higher in the product B group, although the differ-
ence did not reach statistical significance.
In the patients (n ¼ 10) who completed the 6-
month follow-up period a further analysis was
performed. The comparison of the results obtained
after the first infusion and at the end of the crossover
period continued showing statistically significant
differences between the mean of AUC (P ¼ 0.001),
AUMC (P ¼ 0.0008), CL (P ¼ 0.004) and IR (P ¼
0.005) calculated for product A vs. product B.
Furthermore, the Vdss difference also became signi-
ficant (P ¼ 0.026).
The same parameters were analysed in the five
cases treated with product A and B at 3 and
6 months of treatment. When their values were
compared with their respective initial results, no
statistical differences were observed at the 3- and 6-
month periods.
Crossover analysis
anova model was applied to AUC to evaluate the
period effect, the treatment effect and their interac-
tion and so the bioequivalence of preparations A and
B. In Table 3 we can see the anova results (Fisher’s
test) for all the 40 observations we had and for the 24
initial data of our cases finished the crossover study.
As the results of the initial studies when the 24 initial
data were analysed the effect of treat on time
(treatment*period) was marginally significant, ano-
va test for bioequivalence was applied and the
probability for bioequivalence was 5%. When all
40 data were analysed the effect of treat on time
(treatment*period) was no significant and the prob-
ability for bioequivalence was 18%.
Evaluation of prothrombotic activity
In Table 4 we can observe the results of the different
plasma studies performed at preinfusion and 30 min
and 6 h postinfusion in patients when receiving
product A and product B. Thirty minutes after
infusion a significant increment in F1 + 2 and TAT
was observed with Product A and increased F1 + 2
persists 6 h later. After infusion of product B we
observed a marginally significant increment of TAT,
that disappears at 6 h. Platelets increase at 6 h
postinfusion in both groups. The mean values of
Table 2. Pharmacokinetic variables after bolus administration of UMAN COMPLEX DI (product A) and AIMAFIX DI (product B) at
crossover study and after 3 and 6 months of treatment follow-up.
Product/PK parameter Crossover study 3 months 6 months
UMAN COMPLEX DI n ¼ 13 n ¼ 5 n ¼ 5
AUC [0–Tmax] (U h
)1 mL)1) 812.2 ± 195.3* 1059.90 ± 143.2 994.8 ± 127.9
AUMC (v h)2 mL)1) 13404.60* ± 3364.80 17810.90 ± 2544.10 16002.30 ± 3160.20
Incremental recovery (U dL)1 U)1 kg)1) 0.96 ± 0.17** 1.11 ± 0.2 1.08 ± 0.24
MRT (h) 29.7 ± 8.1 28.7 ± 5.1 22.2 ± 3.2
Clearance (mL h)1 kg)1) 5.2 ± 1.4* 3.9 ± 0.4 4.5 ± 0.6
Vdss (mL kg
)1) 154.9 ± 54.9 112.2 ± 27.6 99.2 ± 13.3
Cmax (U mL
)1) 38.8 ± 8.7 56.5 ± 10.1 55.1 ± 11.4
Tmax (h) 0.6 ± 0.8 0.2 ± 0.3 0.3 ± 0.5
T1/2 terminal (h) 22.3 ± 7 20.5 ± 6.6 14.5 ± 2.4
AIMAFIX DI n ¼ 12 n ¼ 5 n ¼ 5
AUC [0–Tmax] (U h
)1 mL)1) 644 ± 132.8 702.9 ± 264.9 850.4 ± 216.4
AUMC (v h)2 mL)1) 10807.40 ± 2740.10 11 193.20 ± 5400.50 13 976.70 ± 3811.70
Incremental recovery (U dL)1 U)1 kg)1) 0.76 ± 0.13 0.78 ± 0.29 0.9 ± 0.3
MRT (h) 30.7 ± 9.2 27.7 ± 12.9 25.3 ± 3.1
Clearance (mL h)1 kg)1) 6.5 ± 1.4 6.8 ± 2.8 5.3 ± 1.6
Vdss (mL kg
)1) 197.5 ± 72.5 164.6 ± 56.2 131.1 ± 25.6
Cmax (U mL
)1) 38.9 ± 6.2 40.1 ± 14.4 46.2 ± 13
Tmax (h) 0.4 ± 0.4 0.5 ± 0.4 0.4 ± 0.5
T1/2 terminal (h) 23.5 ± 12.3 21.6 ± 12.2 17.6 ± 3.5
A vs. B: * P < 0.05; **P < 0.01.
Table 3. Crossover study: area under the curve (anova test).
No. observations
Treatment
effect
Period
effect Interaction
Visit 1–visit 2–visit 3 months–visit 6 months
F 40 13.81 3.89 2.3
P 0.0008 0.0177 0.096
Visit 1 + visit 2
F 24 4.2 0.65 4.2
P 0.053 0.43 0.054
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D-D, ATIII and fibrinogen did not show a significant
change during the observation period.
Follow-up period
During this 6-month period, patients received a
mean of 16 925 UI ± 5927 of product A and
21 220 UI ± 4761 of product B. The majority of
the bleeding episodes were controlled with one
infusion and all the patients experience excellent
response to FIX. No anti-FIX inhibitor was detected
during follow-up period.
Discussion
The in vivo recovery of FIX activity shows a wide
variability between individuals. Values between
25% and 90% have been reported, and it is in
general lower than the expected for FVIII. The
precise mechanism for this lower recovery remains
unclear. There have been implicated some patients
specific factors, and also the higher extravascular
distribution of FIX. It has been suggested that FIX
pharmacokinetics could be influenced by proteolysis
or by binding to unknown inhibitory molecules or
reversible binding of FIX to vascular endothelium
[13–15].
In order to obtain accurate measurement of FIX
activity during a longer period of 72 h, the patients
should receive at least a dose of 75 U kg)1 [9,16].
In our protocol, designed to compare a high purity
FIX concentrate with a PCC, we did not consider
convenient to use a dose larger than 50 U kg)1 of
FIX concentrates. The present study shows that the
IR, terminal half-life, MRT, Vdss and CL of both
products used, are in the range of those reported in
the literature for other high-purity FIX concen-
trates and PCC [16–18]. The terminal half-life
for purified FIX concentrate product B of
23.5 ± 12.3 h found in this study, is comparable
with the reported values for other high purity
concentrates, evaluated in a similar total blood
sampling time of £50 h, (Mononine 23 ± 8.1 h,
Immunine 17 ± 4 h, Nanotiv 19.8 ± 3 h) [17–19]
and it is similar to the PCC product A (22.3 ± 7 h)
used by us. Incremental recovery of Aimafix
(0.76 ± 0.13) is similar to the described for Mon-
onine (0.6 ± 0.14) [17]. Among the four more
important parameters: CL, MRT, Vdss and IR to
consider for bioequivalence [20,21], we have found
significant differences between the two preparations
in CL and IR. The influence of the time elapsed
between infusions of the two study products could
not be discarded. On the contrary, the crossover
study does not show a significant difference in
treatment by period effect, so it seems unlikely that
these differences in FIX behaviour between prod-
ucts would be clinically important. The study
performed 3 and 6 months later on the same
subjects yielded similar pharmacokinetics results.
Table 4. Comparative evaluation of thrombogenicity as measured before a single dose of UMAN COMPLEX DI (product A)/AIMAFIX
DI (product B) at predose, and after 30 min and 6 h.
Predose
UMAN COMPLEX DI (product A) AIMAFIX DI (product B)
Mean SD t-test (P-value) Mean SD t-test (P-value)
Fibrinogen (mg dL)1) 343.77 75.47 – 316.53 58.36 –
ATIII (%) 100.92 9.63 – 92.38 27.22 –
TAT (lg L)1) 1.02 0.66 – 0.86 0.25 –
D-D (lg L)1) 486.69 274.52 – 433.07 305.8 –
F1 + 2 (nm L)1) 0.71 0.38 – 0.79 0.39 –
Platelet (·109 L)1) 243.77 60.74 – 254.53 66.35 –
30 min postinfusion Pre vs. 30 min Pre vs. 30 min
Fibrinogen (mg dL)1) 339.08 76.78 0.70 323.84 62.38 0.37
ATIII (%) 100.46 8.91 0.77 98.76 10.14 0.43
TAT (lg L)1) 2.40 1.09 0.0001 1.39 0.78 0.049
D-D (lg L)1) 511.54 309.32 0.38 414.61 277.27 0.65
F1 + 2 (nm L)1) 2.69 1.03 0.0005 0.71 0.3 0.5
Platelet (·109 L)1) 252.00 59.68 0.11 244.07 48.86 0.32
6 h postinfusion Pre vs. 6 h Pre vs. 6 h
Fibrinogen (mg dL)1) 353.92 72.32 0.17 324.76 64.82 0.52
ATIII (%) 99.31 9.38 0.20 104.84 7.76 0.15
TAT (lg L)1) 1.38 0.63 0.05 1.01 0.55 0.42
D-D (lg L)1) 486.15 263.99 0.92 425.38 227.17 0.88
F1 + 2 (nm L)1) 1.32 0.45 0.00004 0.64 0.36 0.06
Platelet (·109 L)1) 262.69 57.06 0.0016 273.84 57.38 0.028
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In relation to TG, significant differences were
found. The increase in F1 + 2 and in TAT, more than
twice the baseline level, observed with the PCC
(product A) illustrates the coagulation activation
properties of this product. It could make it useful in
some cases of FVIII or FIX inhibitors. On the
contrary, the purified FIX (product B) shows a very
low and transitory formation of TAT, which differs
significantly from the values found with product A,
and speaks in favour of a poor prothrombotic
activity of this product. In regard to TAT levels, it
has been reported that mean TAT values could
increase after infusion of high purity concentrates
but less pronounced than with PCC and possibly
related to its presence in the preparation [18].
In conclusion, the study showed that both plasma-
derived products containing FIX, the high purity
concentrate, product B, as well as the prothrombin
complex concentrate, product A, were well tolerated,
and there was no evidence of inhibitor development
during the follow-up period with both products. Both
products showed clinical efficacy in controlling bleed-
ing episodes in patients during the 6-month follow-up
period. The pharmacokinetic parameters evaluated
are in agreement with those previously observed in
similar preparations of FIX concentrates. The results
in bioequivalence could allow us the use of this PCC in
haemophilia B bleedings. In the case of repeated doses
or the presence of other thrombogenic risk factors
such as liver disease, surgery or prolonged immobil-
ization the potential thrombogenic activity of this
PCC concentrate should be considered so as to take
additional thromboprophylaxis measures individually
in each case or to use purified FIX is available. Similar
considerations must be taken into account if this PCC
is used for the treatment of FII and FX deficiencies.
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